Altre lingue BioMarin Pharmaceutical Inc.

Azioni

BMRN

US09061G1013

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 25/04/2024			Variaz. 5gg	Var. 1 gen.
82,17 ^USD	-9,90%		-8,77%	-14,78%

25/04	BIOMARIN PHARMACEUTICAL INC. : prospettiva positiva di Wells Fargo Securities	ZM
24/04	Transcript : BioMarin Pharmaceutical Inc., Q1 2024 Earnings Call, Apr 24, 2024

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Increase -- Shares Down After Hours	24/04
BioMarin: Q1 Earnings Snapshot	24/04
(BMRN) BIOMARIN PHARMACEUTICAL Forecasts Fiscal Year 2024 EPS Range $2.75 - $2.95	24/04
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 Revenue $648.8M	24/04
Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 EPS $0.71	24/04
BioMarin Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	24/04
BioMarin Reports Record Financial Results for the First Quarter 2024	24/04
BioMarin Pharmaceutical : IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE - Form 8-K	23/04
BioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS Says	22/04
Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing	15/04
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET	10/04
Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing	01/04
New Data to be presented for BioMarin's VOXZOGO in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting	13/03
BioMarin Pharmaceutical Says Voxzogo Leads to Height Gains in Children With Achondroplasia	12/03
ETF der Woche: Auf die Wende der Biotechs setzen	10/03
ETF van de week: inzetten op de ommekeer in de biotech	08/03
ETF de la semaine : miser sur le retournement des Biotechs	08/03
Biomarin Pharmaceutical Insider Sold Shares Worth $348,280, According to a Recent SEC Filing	07/03
BioMarin Pharmaceutical Appoints Cristin Hubbard as Chief Commercial Officer	07/03
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer	07/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue BioMarin Pharmaceutical Inc.

Azioni

BMRN

US09061G1013

Altre lingue

Filtri